Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Domestic equity markets decline for fourth straight session amid H-1B visa concerns
25/09/2025
Polycab India block deal : Promoters likely to sell 0.8% stake worth Rs 887 crore on Thursday : Report
24/09/2025
Akzo Nobel India block deals : Promoter offloads Rs 765 crore stake ; Nippon, Goldman, Citi among buyers
24/09/2025
Rich Dad Poor Dad author Robert Kiyosaki-inspired portfolio surges 40% in 2025 as gold, silver and Bitcoin rally
24/09/2025
Sebi raises net worth requirement for custodians to Rs 75 cr
24/09/2025
Midcap Momentum : 7 stocks reporting rising EPS for 4 consecutive quarters
24/09/2025
